Filing Flows › Actinium Pharmaceuticals (ATNM) › Q3 2025
Actinium Pharmaceuticals (ATNM) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 14, 2025
Actinium Pharmaceuticals (ATNM) reported revenue of $90K for the third quarter 2025 (Q3 2025).
Revenue$90K
Year over year—
Quarter over quarter—
Operating margin—
Net earnings−$5.1M
Actinium Pharmaceuticals, Q3 2025: revenue $90K, net loss $5.1M, operating cash flow −$6.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $90K | — | — |
| Operating profit | −$5.7M | — | — |
| Net earnings | −$5.1M | — | — |
| Operating cash flow | −$6.3M | — | — |
What changed
Revenue was $90K in Q3 2025.
Operating costs exceeded revenue by $5.7M, an operating margin of -6324.4%. The quarter ended with a net loss of $5.1M.
Operating cash flow was −$6.3M. Non-cash charges added back $206K of depreciation and amortization and $109K of share-based compensation. Working capital and other items used $1.5M.
Questions
What was Actinium Pharmaceuticals' revenue in the third quarter 2025?
Actinium Pharmaceuticals (ATNM) reported revenue of $90K for the third quarter 2025 (Q3 2025).